Oregon Health & Science University Center for Health & Healing
Portland, Oregon, 97239, United States
NCT Number: NCT01291940
The goal of this study is to better understand what effect emollients (moisturizers) have on the skin in young children and adults.
Subjects will be recruited from PI and Sub-I clinics and Oregon Health & Science University (OHSU) research opportunities website.
1. Adult and Adolescent Study:
Moisturizer Intervention - There will be 2-3 visits for this study: a screening visit, a baseline visit, and a final visit. Adults with a history of eczema will be asked to apply one of four possible moisturizers to one arm and nothing to the other arm for four weeks. The moisturizers, which will be assigned to the subjects, include either Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, or Vaseline 100% Petroleum Jelly. Subjects can use other skin treatments as needed for their skin condition, but may not treat the arms during the study. Non-invasive tests of the skin will be made at Visit 1 and after four weeks (Visit 2). The skin measurements that will be performed are: * Transepidermal loss (TEWL)- measures how much water is lost across the skin barrier * Skin Cohesion and TEWL - TEWL after 5, 10, 15, and 20 tape strips will measure skin barrier function after tape-stripping * Skin electrical capacitance - measures the moisture in the top layer of skin * Skin pH - measures the acidity of the skin * Stratum corneum cohesion assay - tape-stripping to measure the protein removed from the top layer of skin * Lipidomic analysis - measures the lipids, or oils, in the top layer of skin Control - There will be 1-2 visits for this group: a screening visit and baseline visit, which can be combined. Non-invasive tests of the skin will be taken and include the skin measurements that will be performed are the same as the Moisturizer Intervention group. 2. Pediatric Study: There will be 2-3 visits for this study: a screening visit, a baseline visit, and a final visit. Infants and toddlers between 3 months and 3 years of age without a history of skin barrier diseases will be assigned to a moisturizer, which include either Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, or Aveeno Skin Relief Moisture Repair Cream. Non-invasive tests of the skin will be made at Visit 1 and after four weeks (Visit 2).
* TEWL- measures how much water is lost across the skin barrier * Skin electrical capacitance - measures the moisture in the top layer of skin * Skin pH - measures the acidity of the skin
Looking for future studies?
Notify Me3 month–99 year
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
Other names: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Aveeno Skin Relief Moisture Repair Cream
Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
Other names: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Vaseline 100% Petroleum Jelly
Time frame: 3-4 weeks
Change in TEWL measurements of intervention arms compared to controls.
Oregon Health and Science University
Other
The Effects of Emollient Therapy on the Skin Barrier Function
Acronym: EES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05990725
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Augsburg, Germany
View Trial DetailsNCT07703215
Antioxidant Capacity, Atopic Dermatitis
Cheras, Kuala Lumpur, Malaysia
View Trial DetailsNCT07537751
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
View Trial DetailsNCT06474728
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shanghai, Shanghai Municipality, China
View Trial Details